Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-03-15
2005-03-15
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S303000, C514S019300, C514S403000, C514S405000, C546S118000, C546S119000, C546S120000, C548S360500, C548S360100, C548S363100, C548S364100, C548S366100
Reexamination Certificate
active
06867202
ABSTRACT:
This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula I,where the variables are defined in the specification, or the stereoisomeric mixtures, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomers, or the pharmaceutically acceptable salts and prodrugs thereof to said mammal. The compounds of formula I are growth hormone secretagogues and as such are useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compounds and certain processes useful for the synthesis of said intermediates and th compounds of formula I. This invention is further directed to methods comprising administering to a human or other animal a combination of a functional somatostatin antagonist such as an alpha-2 adrenergic agonist and a compound of formula I.
REFERENCES:
patent: 3202660 (1965-08-01), Zeile et al.
patent: 3235550 (1966-02-01), Behner et al.
patent: 4411890 (1983-10-01), Momany
patent: 4544664 (1985-10-01), Karjalainen et al.
patent: 5492916 (1996-02-01), Morriello et al.
patent: 6107306 (2000-08-01), Carpino et al.
patent: 6110932 (2000-08-01), Carpino et al.
patent: 6124264 (2000-09-01), Carpino et al.
patent: 6127391 (2000-10-01), Hansen et al.
patent: 6248717 (2001-06-01), Carpino et al.
patent: 6448263 (2002-09-01), Carpino et al.
patent: WO 9303419 (1993-02-01), None
patent: WO 9411012 (1994-05-01), None
patent: WO 9413696 (1994-06-01), None
patent: 9513069 (1995-05-01), None
patent: WO 9513069 (1995-05-01), None
patent: WO 9708166 (1997-03-01), None
patent: WO 9709060 (1997-03-01), None
patent: WO 9723508 (1997-07-01), None
patent: WO 9724369 (1997-07-01), None
patent: WO 9858947 (1998-12-01), None
Aloi, et al., “Neuroendocrine Responses to a Novel Growth Homone Secretagogue, L-692,429, in Healthy Older Subjects”,Journal of Endocrinology and Metabolism79(4), pp 943-949 (1994).
Aloia, et al., “Effects of Growth Homone in Osteoporosis”,Journal of Clin. Endocrinol Metab.43, pp. 992-999 (1976).
Arce, et al., “Synergistic Effect of Growth Hormone-Releasing Hormone (GHRH) and clonidine in Stimulating GH Release in Yound and Old Dogs”,Brain Research537, pp. 359-362 (1990).
Arvat, et al., “Synergistic Effect of Growth Hormone-Releasing Hormone Restore the Blunted Growth Hormone-Releasing Activity of Hexarelin in Elderly Subjects”,Journal of Clinical Endocrinology and Metabolism79(5), pp. 1140-1143 (1994).
Binnerts, et al., “The Effects of Human Growth Hormone Administration in elderly Adults with Recent Weight Loss”,Journal of Clinical Endocrinology and Metabolism67(6), pp. 1312-1316 (1988).
Cella, et al., “Combined Administration of Growth-Hormone Releasing Hormone and Clonidine Restores Defective Growth Hormone Secretion in Old Dogs”,Neuroendocrinology57, pp. 432-438 (1993).
Cella, et al., “Presynaptic a2-Adrenergic Stimulation Leads to Growth Hormone Release in the Dog”,Life Sciences34, pp. 447-454 (1984).
Feek, et al., “The Effect of Bromocriptine on Insulin Secretion and Glucose Tolerance in Patients with Acromegaly”,Clinical Endocrinology15, pp. 473-478 (1981).
Gertz, et al., “L-692,429, a Nonpeptide Growth Homone (GH) Secretagogue, Reverses Glucocorticoid Suppression of GH Secretion”,Journal of Clinical Endocrinology and Metabolism79(3), pp. 745-749 (1994).
Hampshire, et al., “Clonidine of Xylazine as Provocative Tests fro Growth Hormone Secretion in the Dog”,Am. Journal of Vet. Research42(6), pp. 1073-1076 (1981).
Hansen, et al., “Insulin Resistance in Acromegaly: Defects in Both Hepatic and Extrahepatic Insulin Action”Am. Journ. Physiol.250, pp. E269-E273 (1986).
Jacks, et al., “Effect of Acute and Repeated Intravenous Administration of I-692,585, a Novel Non-Peptidyl Growth Hormone Secreagogue, on Plasma Growth Hormone, IGF-1, ACTH, Cortisol, Prolactin, Insulin, and Thyroxine Levels in Beagles”,Journal of Endocrinology143, pp. 399-406 (1994).
Jorgensen, et al., “Beneficial Effects of Growth Hormone Treatment in GH-Deficient Adults”,The Lancet, pp. 1221-1224 (1989).
Levine, et al., “Cryohypophysectomy for Acromegaly”,The American Journal of Medicine, 57, pp. 526-535 (1974).
Maccario, et al., “Metabolic Modulation of the Growth Hormone-Releasing Activity of Hexarelin in Man”,Metabolism44(1), pp. 134-138 (1995).
Marcus, et al., “Effects of Short Term Administration of Recombinant Human Growth Hormone to Elderly People”,Journal of Clinical Endocrinology and Metabolism70(2), pp. 519-527 (1990).
Morrison, et al., “Orally Administered Clonidine as a Secretagogue of Growth Hormone and as Thymotrophic Agent in Dogs of Various Ages”,Am. J. Vet. Res.51(1), pp. 65-70 (1990).
Rudman, et al., “Effects of Human Growth Hormone on Body Composition in Elderly Men”,Horm. Res.36(1), pp. 73-81 (1991).
Richelsen, et al., “Growth Hormone Treatment of Obese Women for 5 wk: Effect on Body Composition and Adipose Tissue LPL Activity”,Am. Journ. Physiol.266, pp. E211-E216, (1994).
Thorner, et al., “Growth Hormone-Releasing Hormone and Growth Hormone-Releasing Peptide as Therapeutic Agents to Enhance Growth Hormone Secretion in Disease and Aging”,Recent Progress in Hormone Research52, pp. 215-246 (1997).
Thorner, et al., Abstract 76084 of “Growth Hormone-Releasing Hormone and Growth Hormone-Releasing Peptide as Therapeutic Agents to Enhance Growth Hormone Secretion in Disease and Aging”.
Valcavi, et al., “Alpha-2-Adrenergic Pathways Release Growth Hormone Via a Non-GRF-Dependent Mechanism in Normal Human Subjects”,Clinical Endocrinology29, pp. 309-316 (1988).
Carpino Philip Albert
Chiu Charles Kwok-Fung
Lefker Bruce Allen
Pan Lydia Codetta
Treadway Judith Lee
Crissey Todd M.
Patel Sudhaker B.
Pfizer Inc.
Raymond Richard L.
Wichtowski John A.
LandOfFree
Treatment of insulin resistance does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of insulin resistance, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of insulin resistance will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3458026